News TriSalus Life Sciences, Inc.

Equities

TLSI

US89680M1018

End-of-day quote Nasdaq Other stock markets 03:30:00 25/06/2024 am IST			5-day change	1st Jan Change
5.57 ^USD	-4.30%		-2.62%	-34.08%

03/06	TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial	CI
30/05	Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting	03/06	BU
TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial	03/06	CI
Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target	30/05	MT
Canaccord Genuity Starts Coverage on TriSalus Life Sciences With Buy Rating, $12 Price Target	30/05	MT
TriSalus Life Sciences Launches Warrant Exchange Offer	24/05	MT
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants	24/05	BU
TriSalus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Posts Q1 Revenue $6.5M, vs. Street Est of $5.9M	15/05	MT
TriSalus Reports Q1 2024 Financial Results and Business Update	15/05	BU
TriSalus Life Sciences, Inc. Provides Sales Guidance for the Full Year of 2024	15/05	CI
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors	07/05	BU
TriSalus Life Sciences, Inc. Appoints Liselotte Hyveled to Its Board of Directors	07/05	CI
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call	07/05	BU
TriSalus Life Sciences Obtains $50 Million Debt Facility	01/05	MT
Trisalus Life Sciences, Inc. and Trisalus Operating Life Sciences, Inc. Enters into Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP	01/05	CI
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives	01/05	BU
TriSalus Life Sciences, Inc. announced that it expects to receive $50 million in funding from OrbiMed Advisors LLC	30/04	CI
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update	01/04	BU
TriSalus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
TriSalus Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	01/04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News TriSalus Life Sciences, Inc.

Equities

TLSI

US89680M1018

Summary

Filters